- Home
- VCEL
VCEL
Vericel Corporation
as 11-26-2025 3:36pm EST
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
| Founded: | 1989 | Country: | United States |
| Employees: | N/A | City: | CAMBRIDGE |
| Market Cap: | 2.0B | IPO Year: | 1997 |
| Target Price: | $60.40 | AVG Volume (30 days): | 694.4K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 6 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 0.25 | EPS Growth: | 236.54 |
| 52 Week Low/High: | $29.24 - $63.00 | Next Earning Date: | 11-06-2025 |
| Revenue: | $258,716,999 | Revenue Growth: | 14.05% |
| Revenue Growth (this year): | 18.35% | Revenue Growth (next year): | 22.26% |
Stock Insider Trading Activity of Vericel Corporation (VCEL)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Halpin Michael | VCEL | Chief Operating Officer | Nov 11 '25 | Sell | $40.41 | 2,642 | $106,763.22 | 15,932 | |
| MCLAUGHLIN KEVIN F | VCEL | Director | Nov 10 '25 | Sell | $38.59 | 7,000 | $270,130.00 | 15,100 | |
| Halpin Michael | VCEL | Chief Operating Officer | Nov 6 '25 | Sell | $40.47 | 7,358 | $297,778.26 | 15,932 | |
| Hopper Jonathan Mark | VCEL | Chief Medical Officer | Sep 2 '25 | Sell | $35.77 | 10,000 | $357,700.00 | 66,363 |
Latest Vericel Corporation News
VCEL Breaking Stock News: Dive into VCEL Ticker-Specific Updates for Smart Investing
Insider Monkey
2 months ago
Here’s Why Vericel Corp. (VCEL) Traded Down in Q2
Zacks
3 months ago
Is the Options Market Predicting a Spike in Vericel Stock?
Simply Wall St.
3 months ago
US High Growth Tech Stocks to Watch
Insider Monkey
3 months ago
Leerink Partners Raises the PT Vericel (VCEL), Maintains a Buy Rating
Argus Research
5 months ago
VCEL: Raising target price to $35.00
Simply Wall St.
5 months ago
If EPS Growth Is Important To You, Vericel (NASDAQ:VCEL) Presents An Opportunity
GlobeNewswire
6 months ago
Vericel to Present at the Truist Securities MedTech Conference on Tuesday, June 17, 2025
Argus Research
6 months ago
VCEL: What does Argus have to say about VCEL?
Compare VCEL vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "VCEL Vericel Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.